BCM
SNOA icon

Bridgeway Capital Management’s Sonoma Pharmaceuticals SNOA Stock Holding History

Bridgeway Capital Management’s Portfolio SNOA Stock Details SNOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-795
Closed -$115K – 1405
2020
Q4 		$115K Hold
795
– – ﹤0.01% 1258
2020
Q3 		$133K Buy
+795
New +$122K ﹤0.01% 1230

Other funds holding SNOA

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RE
RBC Europe London, United Kingdom $2.08B AUM 12.2% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bridgeway Capital Management's SNOA Position: Q1 2021 in Review

Bridgeway Capital Management sold out of Sonoma Pharmaceuticals (SNOA) in Q1 2021, closing a stake of 795 shares — an estimated $115K sold.

Bridgeway Capital Management first reported a position in SNOA in Q3 2020 and held it in 2 quarters. The position peaked at $133K in Q3 2020. 17 funds tracked by Wall St. Rank hold SNOA as of Q1 2021.

  • Bridgeway Capital Management reported no remaining Sonoma Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Bridgeway Capital Management sold 795 Sonoma Pharmaceuticals shares in Q1 2021, an estimated $115K.
  • Bridgeway Capital Management first reported a position in Sonoma Pharmaceuticals in Q3 2020 and held it in 2 quarters.
  • Bridgeway Capital Management's Sonoma Pharmaceuticals position peaked at $133K in Q3 2020.
  • 17 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q1 2021.

Based on Bridgeway Capital Management's 13F filing for Q1 2021, filed 17 May 2021.